Loading...
•
Mar 31, 2025
IQVIA Q1 2025 Earnings Report
IQVIA posted solid revenue growth and maintained strong profitability in Q1 2025.
Key Takeaways
IQVIA delivered robust first-quarter results with revenue reaching $3.83B and adjusted EPS of $2.70. TAS outperformed, while R&DS backlog growth highlighted long-term demand resilience.
Revenue reached $3.83 billion, with 2.5% growth YoY
Adjusted EPS came in at $2.70, exceeding expectations
TAS revenue grew 6.4% YoY, performing above target
R&DS backlog expanded to $31.5 billion, up 4.8% YoY
Revenue by Segment
Forward Guidance
IQVIA raised its full-year 2025 revenue outlook due to favorable FX rates while maintaining profit guidance.
Positive Outlook
- Full-year revenue guidance raised by $275 million
- Adjusted EPS guidance reaffirmed at $11.70 to $12.10
- Continued strong TAS performance
- Growing R&DS pipeline and backlog
- Effective navigation of sector challenges
Challenges Ahead
- Customer delays in clinical trial decisions
- Macroeconomic and sector uncertainty
- CSMS segment posted declining revenue
- Free cash flow impacted by capital expenditures
- Net income declined YoY
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...